Last reviewed · How we verify
Prevnar13
Prevnar 13 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae.
Prevnar 13 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in infants and children (2 months to 5 years), Prevention of invasive pneumococcal disease in adults aged 50 years and older, Prevention of pneumococcal otitis media and pneumonia in pediatric populations.
At a glance
| Generic name | Prevnar13 |
|---|---|
| Also known as | Pneumococcal Vaccine, pneumococcal vaccine, 13- valent conjugate pneumococcal vaccine, PCV13, Pneumovax23 |
| Sponsor | GlaxoSmithKline |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae polysaccharide capsule (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains polysaccharide capsules from 13 serotypes of pneumococcus conjugated to a carrier protein, which enhances immunogenicity and promotes T-cell dependent immune responses. This triggers both humoral and cellular immunity, enabling the body to recognize and eliminate pneumococcal bacteria before infection becomes severe. The vaccine is used for prevention of pneumococcal disease across multiple age groups.
Approved indications
- Prevention of invasive pneumococcal disease in infants and children (2 months to 5 years)
- Prevention of invasive pneumococcal disease in adults aged 50 years and older
- Prevention of pneumococcal otitis media and pneumonia in pediatric populations
Common side effects
- Injection site erythema
- Injection site swelling
- Injection site pain
- Fever
- Irritability
- Drowsiness
Key clinical trials
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (PHASE3)
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (PHASE1, PHASE2)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy (PHASE2)
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- Clinical Trial of PCV24 in Infants Aged 2-23 Months (PHASE1)
- Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |